OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer

Background: There is uncertainty about the chemotherapy sensitivity of some oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers. Multiparameter assays that measure the expression of several tumour genes simultaneously have been developed to guide...

Full description

Bibliographic Details
Main Authors: Robert C Stein, Janet A Dunn, John MS Bartlett, Amy F Campbell, Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny L Donovan, Christopher McCabe, Luke Hughes-Davies, Andreas Makris
Format: Article
Language:English
Published: NIHR Journals Library 2016-02-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta20100

Internet

https://doi.org/10.3310/hta20100

Similar Items